The business model of Abbvie Inc is focused on research, development, and commercialization of innovative pharmaceutical products. Abbvie specializes in the discovery and production of drugs primarily in the fields of immunology, oncology, and neuroscience. The company aims to provide effective therapies for various medical conditions, improving the quality of life for patients worldwide. With a strong focus on research and development, Abbvie strives to bring new treatments to market and address unmet medical needs. Through strategic partnerships and collaborations, Abbvie ensures a diversified product portfolio and maintains its position as a leading pharmaceutical company.

Abbvie Inc is primarily active in the pharmaceutical industry.

The main competitors of Abbvie Inc in the market include pharmaceutical companies such as Johnson & Johnson, Pfizer Inc, and Bristol-Myers Squibb Company.

Abbvie Inc is a pharmaceutical company with a rich history and background. It was established in 2013 as a spin-off from Abbott Laboratories. Abbvie focuses on researching, developing, and manufacturing innovative drugs to address various health conditions. With headquarters in North Chicago, Illinois, Abbvie operates on a global scale, delivering advanced therapies to patients worldwide. The company is renowned for its expertise in immunology, oncology, neuroscience, and virology areas. Abbvie has a diverse portfolio of products, including popular brands such as Humira, Imbruvica, and Venclexta, which have positively impacted millions of lives. With a commitment to advancing science and improving patient outcomes, Abbvie continues to make significant contributions to the healthcare industry.

Abbvie Inc, a leading pharmaceutical company, has achieved several significant milestones. In 2013, the company was spun off from Abbott Laboratories, marking a significant step towards establishing its independent identity. Abbvie has also made remarkable progress in the development of innovative therapies. Notably, their drug Humira became a game-changer, becoming the world's best-selling medicine and achieving several regulatory approvals for multiple indications. In addition, Abbvie has expanded its pipeline with the successful launch of new products like Skyrizi and Rinvoq, further strengthening its position in the industry. These accomplishments highlight Abbvie Inc's commitment to advancing healthcare and improving patient outcomes.

Abbvie Inc is primarily present in various countries and regions worldwide. The company has a strong global presence, with a focus on key markets such as the United States, Europe, Asia Pacific, and Latin America. Abbvie Inc operates in multiple countries, including the United Kingdom, Germany, France, Italy, Japan, China, Australia, Brazil, and Mexico, among others. With their international reach, Abbvie Inc continues to expand its business operations and leverage opportunities in different markets to serve a diverse customer base.

Abbvie Inc represents values of innovation, integrity, and a patient-centric approach. With a corporate philosophy focused on discovering and delivering advanced solutions, Abbvie strives to make a remarkable impact on people's lives. The company is committed to advancing science and developing breakthrough treatments in various therapeutic areas, including immunology, oncology, and neuroscience. Abbvie's dedication to excellence and its emphasis on collaboration and ethical practices enable the company to provide transformative healthcare solutions for patients worldwide.

Analysts currently set an average price target of 252,53 USD for the AbbVie stock (median: 249,90 USD), implying -4,3 % versus the latest price. The consensus is based on 37 analyst ratings.

AbbVie Koersdoelstellingen analisten 2026

37 analysts currently rate the AbbVie stock: 25 recommend buying, 12 holding and 0 selling. For 2026, analysts expect AbbVie to generate revenue of 67,35 Miljard USD and earnings per share of 14,04 USD.

AbbVie Koersdoelstellingen analisten 2026

Converted at the current exchange rate, the AbbVie share trades at 224,39 EUR (256,28 USD).

The AbbVie share (ABBV) is listed on 9 stock exchanges, including: NYSE (ABBV), XETRA (4AB.DE), Frankfurt (4AB.F), München (4AB.MU), Düsseldorf (4AB.DU), London (0QCV.L), SIX (Zürich) (ABBV.SW), Wien (ABBV.VI).

Abbvie Inc. is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for some of the world's most serious diseases. This primarily includes oncology, immunological disorders, neurodegenerative diseases, skin diseases, viral and bacterial infections, eye diseases, and metabolic disorders. Abbvie has been an independent company since 2013, following a spin-off from Abbott Laboratories. The company is headquartered in North Chicago, Illinois, USA, and employs over 30,000 people worldwide. Abbvie has four main business segments: 1. Immunology: Approximately 60 percent of Abbvie's revenue comes from the immunology division. The company specializes in the treatment of rheumatoid arthritis, psoriasis, inflammatory bowel diseases, and multiple sclerosis. Key products in the immunology division include Humira, Rinvoq, SkyRizi, and Skyrizi. 2. Hematology and Oncology: Abbvie also has a strong presence in the field of hematology and oncology. Leading products in this segment include Venclexta, Imbruvica, and Mavyret. 3. Neurology: Abbvie also offers products in the field of neurology, such as Skyrizi, Botox, Azelex, and Tazorac. 4. Aesthetic Medicine: The company offers products like Juvederm and Botox in this segment. Abbvie invests heavily in research and development to discover innovative therapies that can improve the lives of patients worldwide. The company has a strong portfolio of patents and prioritizes comprehensive clinical testing in the development of new products to ensure high quality and efficacy. Additionally, the company has formed several collaborative partnerships to accelerate its research and development in various areas. For example, Abbvie has partnered with Biogen in the development of drugs for multiple sclerosis and has cooperated with Alector in the field of neurodegenerative diseases. Abbvie continues to delight its customers with valuable products and services, thereby expanding its leading position in the biopharmaceutical industry. In summary, Abbvie is an innovative and rapidly growing company that plays an important role in the global biopharmaceutical market through its top-notch products and investments in research and development.

De verwachte omzet van AbbVie bedraagt 67,35 Miljard USD. Deze cijfers zijn gebaseerd op huidige financiële gegevens en weerspiegelen de bedrijfsresultaten van het bedrijf.

De verwachte winst van AbbVie bedraagt 24,91 Miljard USD. De nettowinst weerspiegelt de rentabiliteit van het bedrijf na aftrek van alle kosten.

De koers-winstverhouding (P/E) van AbbVie bedraagt momenteel 18,25. De P/E-ratio vergelijkt de huidige aandeelkoers met de winst per aandeel en helpt beleggers de waardering van het AbbVie-aandeel in te schatten.

De koers-omzetverhouding (P/S) van AbbVie bedraagt momenteel 6,75. De P/S-ratio vergelijkt de marktkapitalisatie met de jaarlijkse opbrengsten en dient als waarderingsmaatstaf voor het AbbVie-aandeel.

De Eulerpool Kwaliteitsscore voor AbbVie is 4/10.

De ISIN van AbbVie is US00287Y1091. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.

De WKN van AbbVie is A1J84E. De WKN (Wertpapierkennnummer) is een zescijferig Duits identificatienummer voor wertpapieren.

Het tickersymbool van AbbVie is ABBV. Onder dit beurstickersymbool wordt het AbbVie-aandeel op de beurs verhandeld.

Binnen de laatste 12 maanden betaalde AbbVie een dividend van 6,56 USD . Dit komt overeen met een dividendrendement van ongeveer 2,56 %. Voor de komende 12 maanden zal AbbVie naar verwachting een dividend van 7,37 USD betalen.

De dividendrendement van AbbVie is momenteel 2,56 %.

AbbVie betaalt een dividend uit, dat wordt uitgekeerd in de maanden , , , .

AbbVie betaalde de afgelopen 13 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 7,37 USD verwacht. Dit komt overeen met een dividendrendement van 2,82 %.

AbbVie wordt toegewezen aan de sector 'Gezondheid'.

In het jaar 2025 heeft AbbVie 6,29 USD aan dividenden uitgekeerd.

De dividenden van AbbVie worden in USD uitgekeerd.